



Attorney's Docket No. 35784/209112 (5784-50)

Pre Amended A/#4
J 11/26/01
HAC

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Caligiuri *et al.*
Appl. No.: 09/855,342 Group Art Unit: 1646
Filed: May 14, 2001
For: METHODS OF THERAPY FOR CANCERS CHARACTERIZED
BY OVEREXPRESSION OF THE HER2 RECEPTOR PROTEIN

September 6, 2001

RECEIVED
SEP 14 2001
TECH CENTER 1600/2900

Commissioner for Patents
Washington, DC 20231

PRELIMINARY AMENDMENT

Dear Sir:

Please amend the above-identified application as follows:

In the Specification:

Please rewrite the paragraph at page 28, line 23:

A1 In a phase II study (see reference 11 of the CALGB 9661 Protocol), humanized anti-HER2 was administered to 46 patients with metastatic breast cancer at a weekly intravenous dose of 100 mg following a loading dose of 250 mg. Objective responses were seen in 5 of 43 assessable patients (11.6%), with stable disease reported in 16 additional patients. Antibody trough levels of at least 10 $\mu\text{g/ml}$ were obtained in more than 90% of patients. The mean serum antibody half-life was 8.3 ± 5.0 days. Human anti-human antibodies were not detected in this study. Toxicity was unusual in this study. Eleven moderate-severe toxic events occurred in 768 antibody administrations. These toxicities included fever and chills (5 patients), pain at tumor site (3 patients), diarrhea (2 patients), and nausea and vomiting (1 patient).